Illuminating the Fc dependence of SARS-CoV-2 neutralization
Immunity, ISSN: 1074-7613, Vol: 54, Issue: 9, Page: 1912-1914
2021
- 2Citations
- 14Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- CrossRef1
- Captures14
- Readers14
- 14
Article Description
Monoclonal antibodies show efficacy in treating COVID-19, but the functional requirements for protection are unclear. In this issue of Immunity, Ullah et al. (2021) develop a stable SARS-CoV-2 reporter virus and use bioluminescence imaging to longitudinally monitor infection and assess neutralizing monoclonal antibody interventions in mice. They find that antibody-mediated protection depends on the Fc domain and Fc-gamma receptor-expressing immune cells.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1074761321003587; http://dx.doi.org/10.1016/j.immuni.2021.08.024; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85116955416&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34464594; https://linkinghub.elsevier.com/retrieve/pii/S1074761321003587; https://dx.doi.org/10.1016/j.immuni.2021.08.024
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know